PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) and its derivation 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15) have been shown to reduce glucose metabolism and exhibit potent antitumor activity in several human cancer xenograft models, including tongue carcinoma, gastric cancer and head and neck squamous cell carcinoma.29,55,56 These studies further proved the proto-oncogenic role of PFKFB3. Here, PFKFB3 is linked to gastric cancer.